Src inhibitors in suppression of papillary thyroid carcinoma growth
- 1 June 2013
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 36 (3) , 375-384
Abstract
Background: Papillary thyroid carcinoma is the most common thyroid malignancy. Most papillary thyroid carcinomas contain BRAF mutations or RET/PTC rearrangements, thus providing targets for biologic therapy. Our previous studies had suggested papillary thyroid carcinomas (PTCs) with a BRAF mutation and the RET/PTC1 rearrangement have different sensitivities to MEK1/2 inhibitors, suggesting different signaling transduction pathways were involved.Methods: Src signaling transduction pathway in PTC cells was examined using Src inhibitors (PP2, SU6656, or dasatinib) and si‐Src RNA in vitro by Western blot analysis and proliferation analysis. An orthotopic xenograft mouse model was used for the in vivo studies using dasatinib.Results: In PTC cells, Src inhibitors suppressed p‐Src and p‐FAK and inhibited cell growth. In addition, significant suppression and extension of the p‐ERK1/2 dephosphorylation were detected in RET/PTC1‐rearranged cells in combination with an MEK inhibitor (CI‐1040). The Src family kinase/ABL inhibitor, dasatinib, significantly decreased tumor volume in mice inoculated with PTC cells carrying the RET/PTC1 rearrangement. In BRAF‐mutated PTC cells, Src inhibitors effectively suppressed p‐Src expression and dasatinib significantly decreased tumor volume with twice daily treatment.Conclusion: Src inhibitors effectively inhibited the Src signaling transduction pathway in PTC cells in vitro and dasatinib suppressed tumor growth in vivo. These results suggested that Src signaling transduction pathway plays an important role in regulating growth in PTC cells. Combination of Src and MEK1/2 inhibitors extended the dephosphorylation of extracellular signal‐regulated kinase (ERK)1/2 in PTCs carrying the RET/PTC1 rearrangement suggesting that combination therapy with complementary inhibitors of other signaling transduction pathways may be needed to effectively suppress growth and induce apoptosis in these cells. © 2013 Wiley Periodicals, Inc. Head Neck 36: 375–384, 2014Keywords
This publication has 25 references indexed in Scilit:
- SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid CancerClinical Cancer Research, 2012
- Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell lineMolecular Cancer, 2010
- MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivoMolecular Cancer Therapeutics, 2010
- Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung CancerClinical Cancer Research, 2009
- Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2009
- Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinibBlood, 2008
- Extent of Surgery Affects Survival for Papillary Thyroid CancerAnnals of Surgery, 2007
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- A renaissance for SRCNature Reviews Cancer, 2004
- Mutations of the BRAF gene in human cancerNature, 2002